Emergent Coronary Thrombectomy for Acute Myocardial Infarction Immediately Following Craniotomy with Tumor Resection.
Curtis R GinderGiselle A Suero-AbreuSaad S GhummanBrian A BergmarkOmar ArnaoutRobert P GiuglianoPublished in: Cardiology and therapy (2024)
The management of perioperative acute myocardial infarction (AMI) following oncologic neurosurgery requires balancing competing risks of myocardial ischemia and postoperative bleeding. There are limited human data to establish the safest timing of antiplatelet or anticoagulation therapy following neurosurgical procedures. For patients with malignancy experiencing AMI in the acute postoperative period, staged percutaneous coronary intervention (PCI) with upfront coronary aspiration thrombectomy followed by delayed completion PCI may offer an opportunity for myocardial salvage while minimizing postoperative bleeding risks. CYP2C19 genotyping and platelet aggregation studies can help confirm adequate platelet inhibition once antiplatelet therapy is resumed.
Keyphrases
- acute myocardial infarction
- percutaneous coronary intervention
- antiplatelet therapy
- coronary artery disease
- atrial fibrillation
- patients undergoing
- st segment elevation myocardial infarction
- acute coronary syndrome
- st elevation myocardial infarction
- coronary artery bypass grafting
- left ventricular
- coronary artery bypass
- coronary artery
- acute ischemic stroke
- endothelial cells
- human health
- electronic health record
- venous thromboembolism
- heart failure
- prostate cancer
- aortic stenosis
- ultrasound guided
- cardiac surgery
- mesenchymal stem cells
- intensive care unit
- stem cells
- aortic dissection
- genome wide
- bone marrow
- gene expression
- cell therapy
- drug induced
- machine learning
- case control
- pluripotent stem cells
- robot assisted
- dna methylation
- replacement therapy
- high throughput